Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC

Journal:

Science Advances

Published:

2025-10-17

DOI:

10.1126/sciadv.ady7930

Affiliations:

6

Authors:

13

Go to article

Institutions	Authors	Share
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, China	10.000000 10.000000	0.77
Institute of Process Engineering (IPE), CAS, China	1.000000	0.08
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.08
Zhongshan Hospital, Fudan University, China	0.333333	0.03
Zhejiang University School of Medicine, China	0.333333	0.03
Lishui Municipal Central Hospital, China	0.333333	0.03

Interested in Oncology and Carcinogenesis?